Ludwig Institut für Krebsforschung AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Capecitabine and 131I-huA33 in Patients With Metastatic Colorectal Cancer

Phase 1

Completed

Conditions: Colorectal Neoplasms

Interventions: Drug: Capecitabine
Drug: 131I-huA33 (131-Iodine on humanised monoclonal antibody A33)

First Posted Date: 2006-02-14

Last Posted Date: 2022-10-10

Lead Sponsor: Ludwig Institute for Cancer Research

Target Recruit Count: 19

Registration Number: NCT00291486

Locations: 🇦🇺
Ludwig Institute Oncology Unit and Tumor Targeting Program, Austin Health, Heidelberg, Victoria, Australia

Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.

Phase 1

Completed

Conditions: Cancer of Kidney
Renal Cancer
Kidney Cancer
Renal Neoplasms
Renal Cell Carcinoma (RCC)
Clear Cell Renal Cell Carcinoma
Neoplasms, Kidney

Interventions: Drug: 124-Iodine-cG250 (124I-cG250)

First Posted Date: 2005-09-20

Last Posted Date: 2022-10-10

Lead Sponsor: Ludwig Institute for Cancer Research

Target Recruit Count: 26

Registration Number: NCT00199888

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250

Phase 1

Completed

Conditions: Kidney Neoplasm
Renal Cancer
Renal Cell Carcinoma
Kidney Cancer

Interventions: Drug: Yttrium-90 conjugated chimeric G250 (^90Y-DOTA-cG250)

First Posted Date: 2005-09-20

Last Posted Date: 2022-10-10

Lead Sponsor: Ludwig Institute for Cancer Research

Target Recruit Count: 18

Registration Number: NCT00199875

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide® ISA-51 in Patients With Cancer.

Phase 1

Completed

Conditions: Cancer
Neoplasm

Interventions: Biological: NY-ESO-1b peptide plus CpG 7909 and Montanide® ISA-51

First Posted Date: 2005-09-20

Last Posted Date: 2022-10-10

Lead Sponsor: Ludwig Institute for Cancer Research

Target Recruit Count: 14

Registration Number: NCT00199836

Locations: 🇩🇪
Krankenhaus Nordwest, Frankfurt, Germany

Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma

Phase 2

Completed

Conditions: Melanoma

Interventions: Biological: NY-ESO-1 ISCOMATRIX®
Biological: ISCOMATRIX® adjuvant

First Posted Date: 2005-09-20

Last Posted Date: 2022-10-12

Lead Sponsor: Ludwig Institute for Cancer Research

Target Recruit Count: 111

Registration Number: NCT00199901

Locations: 🇦🇺
Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
🇦🇺
Austin Health (Ludwig Institute Oncology Unit), Heidelberg, Victoria, Australia
🇦🇺
Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia

and more 12 locations

Phase I Trial of huA33 Plus Chemotherapy in Patients With Metastatic Colorectal Cancer

Phase 1

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Oxaliplatin
Drug: 5-Fluorouracil
Drug: Leucovorin
Drug: huA33

First Posted Date: 2005-09-20

Last Posted Date: 2022-10-10

Lead Sponsor: Ludwig Institute for Cancer Research

Target Recruit Count: 20

Registration Number: NCT00199797

Locations: 🇨🇭
UniversitaetsSpital Zuerich, Zurich, Switzerland
🇩🇪
Krankenhaus Nordwest, Frankfurt, Germany

NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine

Phase 1

Completed

Conditions: Prostate Cancer
Sarcoma
Esophageal Cancer
Bladder Cancer
Non-small Cell Lung Cancer

Interventions: Biological: NY-ESO-1 Plasmid DNA Cancer Vaccine

First Posted Date: 2005-09-20

Last Posted Date: 2022-10-10

Lead Sponsor: Ludwig Institute for Cancer Research

Target Recruit Count: 18

Registration Number: NCT00199849

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
New York Presbyterian Hospital, New York, New York, United States

Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma

Phase 1

Terminated

Conditions: Malignant Melanoma

Interventions: Biological: MAGE-3.A1 peptide and CpG 7909

First Posted Date: 2005-09-05

Last Posted Date: 2022-10-07

Lead Sponsor: Ludwig Institute for Cancer Research

Target Recruit Count: 1

Registration Number: NCT00145145

Locations: 🇧🇪
Cliniques Universitaires Saint-Luc (UCL), Brussels, Belgium
🇧🇪
Ludwig Institute for Cancer Research, Brussels, Belgium

Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma

Phase 1

Terminated

Conditions: Malignant Melanoma

Interventions: Biological: 8 HLA-A2-restricted peptides and CpG 7909
Biological: 8 HLA-A2-restricted peptides and Montanide ISA51

First Posted Date: 2005-09-05

Last Posted Date: 2022-10-10

Lead Sponsor: Ludwig Institute for Cancer Research

Target Recruit Count: 23

Registration Number: NCT00145158

Locations: 🇧🇪
Clinique Universitaires St-Luc, Brussels, Belgium
🇧🇪
Ludwig Institute for Cancer Research, Brussels, Belgium

Phase I/II Dose-escalation Study of Lutetium-177-labeled cG250 in Patients With Advanced Renal Cancer

Phase 1

Completed

Conditions: Metastatic Renal Cell Carcinoma

Interventions: Drug: 111-In-DOTA-cG250
Drug: 177-Lu-DOTA-cG250

First Posted Date: 2005-09-02

Last Posted Date: 2022-10-28

Lead Sponsor: Ludwig Institute for Cancer Research

Target Recruit Count: 26

Registration Number: NCT00142415

Locations: 🇳🇱
University Medical Center Nijmegen, Nijmegen, Netherlands

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy